retatrutide clinical trial results 2024 2025 press release produces up to 30.3% weight loss in Phase 3 A review of an investigational

The absence of accessible contact information on the main site as of this review is a second practical concern - a guarantee you can't activate isn't a guarantee

Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial

A randomized trial found that low-dose semaglutide significantly decreased: The amount of alcohol consumed during laboratory self-administration tasks 22 Weekly alcohol cravings compared to placebo 22 Drinks per drinking day 22 The magnitude of these effects appears substantial, with medium to large effect sizes for grams of alcohol consumed (, 0.48) and peak breath alcohol concentration (, 0.46) 22

Furthermore, medication alone is rarely a magic cure-all